Skip to main content

Main utility

  • Browse negotiations
  • Careers
  • Contact us
  • News
Français FR
Home Home

Main navigation

  • Inside the pCPA
    • Our purpose
      • Our vision and strategy
      • What we do
    • Our people
      • Governance
      • Members
      • Who we are
  • Insights and updates
    • Our public reimbursement system
      • Drugs we negotiate
      • Our role in the drug reimbursement system
      • Glossary
    • Our updates
      • News
      • Recent negotiation activity
    • Our impact
      • Performance dashboard
      • Reports
  • Negotiations
    • Negotiation activity
      • Browse negotiations
      • Recent negotiation activity
    • Drug categories
      • Brand-name drugs
      • Biosimilar drugs
      • Generic drugs
    • Processes and frameworks
      • Standard negotiation process
      • Expedited negotiation pathways
      • Early negotiation process
      • Targeted negotiation process
      • Temporary access process
      • Biosimilar drug review process
      • Tiered pricing framework
      • Centralized price change process
Français FR

Main navigation

  • Inside the pCPA
    • Our purpose
      • Our vision and strategy
      • What we do
    • Our people
      • Governance
      • Members
      • Who we are
  • Insights and updates
    • Our public reimbursement system
      • Drugs we negotiate
      • Our role in the drug reimbursement system
      • Glossary
    • Our updates
      • News
      • Recent negotiation activity
    • Our impact
      • Performance dashboard
      • Reports
  • Negotiations
    • Negotiation activity
      • Browse negotiations
      • Recent negotiation activity
    • Drug categories
      • Brand-name drugs
      • Biosimilar drugs
      • Generic drugs
    • Processes and frameworks
      • Standard negotiation process
      • Expedited negotiation pathways
      • Early negotiation process
      • Targeted negotiation process
      • Temporary access process
      • Biosimilar drug review process
      • Tiered pricing framework
      • Centralized price change process

Main utility

  • Browse negotiations
  • Careers
  • Contact us
  • News
  • Home /
  • Listing 3 - Actual negotiations

Listing 3 - Actual negotiations

Search by drug, manufacturer, or indication

Displaying 571 - 580 of 1165

MAR-Trientine (trientine)

Status:

Concluded with an LOI

Manufacturer:

Marcan Pharmaceuticals Inc.

Indication:

Wilson's Disease

Last updated March 25, 2022

Aybintio (bevacizumab)

Status:

Concluded with an LOI

Manufacturer:

Organon Canada Inc.

Indication:

Metastatic Colorectal Cancer (mCRC); Locally Advanced, Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC); Platinum-Sensitive Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer; Platinum-Resistant Recurrent Epithelial Ovarian, Fallopian Tube and Primary Peritoneal Cancer; and Malignant Glioma (WHO Grade IV) - Glioblastoma

Last updated March 16, 2022

Darzalex SC (Daratumumab)

Status:

Concluded with an LOI

Manufacturer:

Janssen Inc.

Indication:

Light chain amyloidosis (AL), newly diagnosed in adult patients (in combination with bortezomib, cyclophosphamide, and dexamethasone)

Last updated March 11, 2022

Remsima SC (infliximab)

Status:

Concluded without agreement

Manufacturer:

Celltrion Healthcare Canada Ltd.

Indication:

Rheumatoid Arthritis

Last updated March 10, 2022

Insulin pumps and pump supplies (Insulin pumps and pump supplies)

Status:

Concluded with an LOI

Manufacturer:

Ypsomed Canada Inc.

Indication:

Diabetes Mellitus, Type 1 & 2

Last updated March 8, 2022

Insulin pumps and pump supplies (Insulin pumps and pump supplies)

Status:

Concluded with an LOI

Manufacturer:

Medtronic Canada

Indication:

Diabetes Mellitus, Type 1 & 2

Last updated March 8, 2022

Simlandi (adalimumab)

Status:

Concluded with an LOI

Manufacturer:

Jamp Pharma Corporation

Indication:

Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis

Last updated March 3, 2022

Kesimpta (ofatumumab)

Status:

Concluded with an LOI

Manufacturer:

Novartis Pharmaceuticals Canada Inc.

Indication:

Multiple Sclerosis, Relapsing-Remitting

Last updated March 2, 2022

Yuflyma (adalimumab)

Status:

Concluded with an LOI

Manufacturer:

Celltrion Healthcare Canada Ltd.

Indication:

Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis

Last updated March 1, 2022

Abrilada (adalimumab)

Status:

Concluded with an LOI

Manufacturer:

Pfizer Canada ULC

Indication:

Rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, plaque psoriasis, uveitis

Last updated February 28, 2022

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 56
  • Page 57
  • Current page 58
  • Page 59
  • Page 60
  • …
  • Next page Next ›
  • Last page Last »

Page updated: February 12, 2026

Our team is located across the country, on the ancestral and unceded territories of Canada’s Indigenous Peoples. We recognize their inherent and treaty rights, and we’re grateful to stand, live, and work on these lands.

pan-Canadian Pharmaceutical Association

General inquiries: Email us

Footer Navigation

  • Inside the pCPA
    • Who we are
    • What we do
    • Our vision and strategy
    • Governance
    • Members
  • Insights and updates
    • Our role
    • Drugs we negotiate
    • Performance dashboard
    • News
    • Glossary
  • Negotiations
    • Recent negotiation activity
    • Standard negotiations
    • Expedited pathways
    • Biosimilar drugs
    • Brand-name drugs
    • Generic Drugs

Footer secondary

  • Browse negotiations
  • Careers
  • Contact us
  • News

Copyright © 2026 pan-Canadian Pharmaceutical Alliance. All rights reserved.

Footer Utility

  • Privacy Policy
  • Terms of use